Screener
CytomX Therapeutics CTMX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies | ||
| Stockholders' equity: | ||
| Convertible preferred stock | — | — |
| Common stock | 2 | 2 |
| Additional paid-in capital | 1,053,125 | 810,844 |
| Accumulated other comprehensive income | (196) | 111 |
| Accumulated deficit | (750,863) | (711,949) |
| Total stockholders' equity | 302,068 | 99,008 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's common stock?
- CytomX Therapeutics (CTMX) reported common stock of $2K in Q2 2026.
- How has CytomX Therapeutics's common stock changed year-over-year?
- CytomX Therapeutics's common stock decreased by 0.0% year-over-year, from $2K to $2K.
- What is the long-term trend for CytomX Therapeutics's common stock?
- Over 5 years (2020 to 2025), CytomX Therapeutics's common stock has grown at a 14.9% compound annual growth rate (CAGR), from $1K to $2K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about CytomX Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude